

B-Cell Lymphoma
Raji Cells
Relative surface binding
(% of control)
120
80
40
0
0
1
10
100
μM
PQ912
IC50=5.95μM
Compound 32
IC50=1.38 μM
Compound 34
IC50=1.1 μM
Compound 30
IC50=0.84 μM

Figure 1A.



Colon Cancer
DLD-1 Cells
Relative surface binding
(% of control)
120
80
40
0
0
1
10
100
μM
PQ912
IC50=3.19 μM
Compound 32
IC50=793 nM
Compound 34
IC50=575.9 nM
Compound 30
IC50=1.01 μM

Figure 1B.



Ovarian Cancer
SK-OV-3 cells
Relative surface binding
(% of control)
120
90
60
30
0
0
1
10
100
μM
PQ912
IC50=149.7 nM
Compound 32
IC50=201.1 nM
Compound 34
IC50=190.0 nM

Figure 1C.



Anti-hCD47 CC2C6 Antibody
Relative surface binding, % of DMSO
120
80
40
0
*
*
* **
* **
DMSO
PQ912 10 µM
Compound 30 10 µM
Compound 32 10µM
Compound 34 10µM

Figure 2A.



Anti-hCD47 2D3 Antibody
Relative surface binding, % of DMSO
150
100
50
0
DMSO
PQ912 10μM
Compound 30 10μM
Compound 32 10μM
Compound 34 10μM

Figure 2B.



B-Cell Lymphoma
Raji Cells
Relative surface binding, % of DMSO
120
80
40
0
*, **
*, **
DMSO
PQ912 10 µM
Compound 32 10µM
Compound 34 10µM

Figure 3A.



Colon Cancer
DLD-1 Cells
Relative surface binding, % of DMSO
120
80
40
0
*
*
*
DMSO
PQ912 10 µM
Compound 32 10 µM
Compound 34 10 µM

Figure 3B.



Ovarian Cancer
SK-OV-3 cells
Relative surface binding, % of DMSO
120
80
40
0
*
*
*
DMSO
PQ912 10 µM
Compound 32 10 µM
Compound 34 10 µM

Figure 3C.



Phagocytosis, %
100
80
60
40
20
0
0.0
0.5
1.0
1.5
2.0
2.5
Rituximab, μM
DMSO
10 μM Compound 34
10 μM PQ912
Rituximab
Rituximab +
10 μM Compound 34
Rituximab +
10 μM PQ912

Figure 4A.



Phagocytosis,
% Increase vs. Rituximab
20
15
10
5
0
0.0
0.5
1.0
1.5
2.0
2.5
Rituximab, μM
Rituximab +
10 μM Compound 34
Rituximab +
10 μM PQ912

Figure 4B



B-Cell Lymphoma
Raji Xenograft Model
Vehicle Control
100 mg/kg Compound 34
10 mg/kg Rituxamab
Combination
Tumor Volume, mm3
2000
1500
1000
500
0
0
5
10
15
20
Days Post Treatment
*
*, **
**
*: p<0.05 vs. Vehicle Control
**: p<0.05 vs. Single Agents

Figure 5A



B-Cell Lymphoma
Raji Xenograft Model
Body Weight Change, % Initial
15
10
5
0
-5
5
10
15
20
Days Post Treatment
Vehicle Control
100 mg/kg Compound 34
10 mg/kg Rituxamab
Combination

Figure 5B



Rituximab
Drug Treatment (Day 1 to Day 18)
No Treatment (Day 19 on)
Tumor Volume, mm3
2000
1500
1000
500
0
0
10
20
30
40
50
60
70
80
90
Days

Figure 5C



Rituximab + Compound 34
Drug Treatment (Day 1 to Day 18)
No Treatment (Day 19 on)
Tumor Volume, mm3
2000
1500
1000
500
0
0 10 20 30 40 50 60 70 80 90
Days

Figure 5D



Drug Treatment (Day 1 to Day 18)
No Treatment (Day 19 on)
Vehicle Control
100 mpk Compound 34
20 mpk Rituximab
Rituximab + Compound 34
Probability of Survival
100
50
0
0 10 20 30 40 50 60 70 80 90
Days
Median Survival Days
Vehicle Control: 15.5 days
BPRQC298: 18 days
Rituximab: 28 days
Combination: 47 days

Figure 5E



B-Cell Lymphoma
Raji Xenograft Model
Vehicle Control
10 mg/kg Rituxamab
10 mg/kg Compound 34 + 10 mg/kg Rituxamab
30 mg/kg Compound 34 + 10 mg/kg Rituxamab
100 mg/kg Compound 34 + 10 mg/kg Rituxamab
Tumor Volume, mm3
1200
900
600
300
0
0
10
20
30
40
Days Post Treatment

Figure 6



Compound 34 Concentration in the Plasma and Tumor
100000
10000
1000
ng/mL (Plasma)
ng/g (Tumor)
0
5
10
15
20
25
Hours Post Last Dose
Compound 34 Plasma
Compound 34 Tumor

Figure 7



80
60
40
20
0
%CC2C6+ Cells
(In Total CD47+ Cells)
Vehicle Control
100 mg/kg Compound 34
*

Figure 8A



Vehicle Control
100 mg/kg Compound 34
Total CD47+Cells
(% Live Cells)
120
90
60
30
0

Figure 8B